Table 4.
Efficacy of CAG regimen in AML patients according to karyotypes
| Study | Year |
Total No. patients |
No. Patients | No. CR | CR % | ||||||
| Favorable | Intermediate | Unfavorable | Favorable | Intermediate | Unfavorable | Favorable | Intermediate | Unfavorable | |||
| Saito [38] | 2000 | 63 | 6 | 27 | 30 | 5 | 19 | 9 | 83 | 70 | 29 |
| Hirayama [39] | 2003 | 9 | 1 | 4 | 4 | 1 | 3 | 2 | 100 | 75 | 50 |
| Qian [20] | 2007 | 40 | 2 | 28 | 10 | 1 | 19 | 4 | 50 | 68 | 40 |
| Chen [46] | 2008 | 34* | 6 | 16 | 9 | 6 | 13 | 2 | 100 | 81 | 22 |
| Zhu [50] | 2009 | 30 | 4 | 21 | 5 | 2 | 12 | 0 | 50 | 57 | 0 |
| Ma [28] | 2010 | 31 | 3 | 18 | 10 | 1 | 14 | 2 | 33 | 78 | 20 |
Abbreviation: AML: acute myeloid leukemia; CR: complete remission; CAG: cytarabine, aclarubicin and G-CSF; *: karyotyping from 3 patients was indeterminate.